Reported Reactions

Reactions

MedDRA preferred term

Poisoning deliberate: adverse event reports recording this term

9,182 reports to FDA record it, 2004–2026; 0% of the database.

9,182
reports recording the term
0% of all reports
1,223
reports, 12 months to June 2026
1,056 in the 12 months before
100%
marked serious by the reporter
57.4% across all reports
16.7%
record death among outcomes, as reported
9.1% across all reports

9,182 reports in FDA's adverse event database record the MedDRA term "Poisoning deliberate": 0% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

1,223 reports recorded it in the 12 months to June 2026, up 16% from 1,056 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 100% are marked serious, 16.7% include death among the outcomes and 64.8% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Acetaminophen, Alprazolam and Diazepam. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

093185Jul 2021: 75Aug 2021: 105Sep 2021: 56Oct 2021: 68Nov 2021: 57Dec 2021: 462022Jan 2022: 33Feb 2022: 61Mar 2022: 83Apr 2022: 103May 2022: 93Jun 2022: 185Jul 2022: 107Aug 2022: 51Sep 2022: 84Oct 2022: 61Nov 2022: 76Dec 2022: 862023Jan 2023: 102Feb 2023: 82Mar 2023: 86Apr 2023: 51May 2023: 61Jun 2023: 68Jul 2023: 125Aug 2023: 64Sep 2023: 64Oct 2023: 60Nov 2023: 79Dec 2023: 592024Jan 2024: 77Feb 2024: 96Mar 2024: 88Apr 2024: 75May 2024: 107Jun 2024: 81Jul 2024: 137Aug 2024: 90Sep 2024: 88Oct 2024: 113Nov 2024: 49Dec 2024: 842025Jan 2025: 84Feb 2025: 96Mar 2025: 84Apr 2025: 74May 2025: 77Jun 2025: 80Jul 2025: 120Aug 2025: 81Sep 2025: 66Oct 2025: 87Nov 2025: 138Dec 2025: 1212026Jan 2026: 48Feb 2026: 132Mar 2026: 124Apr 2026: 106May 2026: 78Jun 2026: 122

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

DrugClassReports with this termShare of the drug's own reports
AcetaminophenNonsteroidal anti-inflammatory drug1,4091.6%
AlprazolamBenzodiazepine1,1722.4%
DiazepamBenzodiazepine8872.2%
Paracetamol—7652.7%
Tramadol—7451.6%
QuetiapineAtypical antipsychotic7271.4%
Zopiclone—6564.6%
VenlafaxineSerotonin and norepinephrine reuptake inhibitor6352.1%
OxazepamBenzodiazepine5605.2%
Cyamemazine—49812.8%
IbuprofenNonsteroidal anti-inflammatory drug4150.5%
Mirtazapine—4071.2%
Bromazepam—4037%
SertralineSerotonin reuptake inhibitor3820.9%
ParoxetineSerotonin reuptake inhibitor3632.2%
Zolpidemgamma-Aminobutyric acid A receptor positive modulator3541.9%
Tramadol hydrochlorideOpioid agonist3291.2%
Alcohol—3271.4%
OlanzapineAtypical antipsychotic3240.7%
LorazepamBenzodiazepine2760.8%
Cocaine—2521.3%
ValiumBenzodiazepine2432.5%
Codeine—2331.1%
XanaxBenzodiazepine2331.3%
Propranololbeta-Adrenergic blocker2321.7%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

ClassReports with this termShare of class reportsMedian drug in class
Benzodiazepine3,5791.5%0.3%
Nonsteroidal anti-inflammatory drug2,2020.4%0%
Atypical antipsychotic1,7770.3%0%
Serotonin reuptake inhibitor1,6230.6%0.5%
Opioid agonist1,2340.1%0%
Serotonin and norepinephrine reuptake inhibitor8680.5%0.1%
Anti-epileptic agent6700.2%0%
beta-Adrenergic blocker5760.4%0%
gamma-Aminobutyric acid A receptor positive modulator4111.2%0.7%
Biguanide2370.2%0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.3%27
2 to 110.5%47
12 to 1711.5%1,056
18 to 4440.1%3,678
45 to 6425.2%2,311
65 to 745.4%499
75 and over4.7%431
Age not given12.3%1,133

Patient sex

Female55.5%5,099
Male33.8%3,106
Not given10.6%977

Grey bar: all 20,646,523 reports in the database. 8.9% of these reports give the United States as the country.

Questions about "Poisoning deliberate"

What does "Poisoning deliberate" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record poisoning deliberate?

9,182 reports through June 2026 (0% of all reports), 1,223 of them in the latest 12 months.

Which drugs appear most often in these reports?

Acetaminophen (1,409), Alprazolam (1,172), Diazepam (887), Paracetamol (765) and Tramadol (745). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.